X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2023
Details:
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Lead Product(s): Coenzyme Q10,Vitamin E
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Qunol CoQ10
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2023
Details:
The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Lead Product(s): Coenzyme Q10
Therapeutic Area: Rare Diseases and Disorders Product Name: BPM31510
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Debra of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Details:
Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Lead Product(s): Coenzyme Q10,Caspofungin
Therapeutic Area: Genetic Disease Product Name: Ubiquinone
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clarus
Deal Size: $40.8 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement September 16, 2021
Details:
Ubiquinol (the active form of CoQ10) significantly improved FMD in both treated groups compared with the placebo group (Ubiquinol 200 mg/day; Ubiquinol 100 mg/day; placebo).
Lead Product(s): Coenzyme Q10
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ubiquinol
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
